Klotho suppresses tumor progression via inhibiting IGF-1R signaling in T‑cell lymphoma

Zhou,Xiangxiang; Zhang,Ya; Li,Ying; Xu,Yangyang; Zhang,Lingyan; Li,Ying; Wang,Xin

doi:10.3892/or.2017.5744

Klotho suppresses tumor progression via inhibiting IGF-1R signaling in T‑cell lymphoma

Authors:
- Xiangxiang Zhou
- Ya Zhang
- Ying Li
- Yangyang Xu
- Lingyan Zhang
- Ying Li
- Xin Wang
View Affiliations

Affiliations: Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/or.2017.5744
Pages: 967-974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Klotho is a transmembrane protein and acts as an upstream modulator of insulin-like growth factor-1 receptor (IGF-1R) signaling, which was indicated to be involved in the pathogenesis of solid cancer and hematological malignancies, including T‑cell lymphoma. Although Klotho was recently identified as a tumor suppressor in several types of human malignancies, the potential role of Klotho in T‑cell lymphoma has not been reported. In the present study, we investigated the expression level and the molecular events of Klotho in T‑cell lymphoma. Significantly lower expression of Klotho was observed in T‑cell lymphoma patient samples compared to normal lymph nodes. Functional analysis after Klotho overexpression revealed significantly inhibited tumor cell viability in T‑cell lymphoma. Moreover, apoptosis of T‑cell lymphoma cells were induced after transfected with Klotho-overexpressing vectors. Forced expression of Klotho resulted in decline of activation of IGF-1R signaling, accompanied by decreased phosphorylation of its downstream targets, including AKT and ERK1/2. These data indicated that Klotho acts as a tumor suppressor via inhibiting IGF-1R signaling, thus suppressing the viability and promoting apoptosis in T‑cell lymphoma. Taken together, Klotho may serve as a potential target for the therapeutic intervention of T‑cell lymphoma.

View Figures

View References

1	Zhao WL: Targeted therapy in T-cell malignancies: Dysregulation of the cellular signaling pathways. Leukemia. 24:13–21. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
3	Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, et al: Suppression of aging in mice by the hormone Klotho. Science. 309:1829–1833. 2005. View Article : Google Scholar : PubMed/NCBI
4	Kuro-o M: Klotho and aging. Biochim Biophys Acta. 1790:1049–1058. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, et al: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 280:38029–38034. 2005. View Article : Google Scholar : PubMed/NCBI
6	Zhou X and Wang X: Klotho: A novel biomarker for cancer. J Cancer Res Clin Oncol. 141:961–969. 2015. View Article : Google Scholar : PubMed/NCBI
7	Dai D, Wang Q, Li X, Liu J, Ma X and Xu W: Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1. Oncol Rep. 35:552–558. 2016.PubMed/NCBI
8	Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, Zundelevich A, Evron E, Gal-Yam EN, Kaufman B and Wolf I: Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat. 133:649–657. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chang B, Kim J, Jeong D, Jeong Y, Jeon S, Jung SI, Yang Y, Kim KI, Lim JS, Kim C, et al: Klotho inhibits the capacity of cell migration and invasion in cervical cancer. Oncol Rep. 28:1022–1028. 2012.PubMed/NCBI
10	Yaktapour N, Ubelhart R, Schuler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, et al: Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 122:1621–1633. 2013. View Article : Google Scholar : PubMed/NCBI
11	Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ and Amin HM: Expression and effects of inhibition of type I in sulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Haematologica. 96:871–880. 2011. View Article : Google Scholar : PubMed/NCBI
12	Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS and Samaniego F: Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 8:632015. View Article : Google Scholar : PubMed/NCBI
13	Groen RW, Oud ME, Schilder-Tol EJ, Overdijk MB, ten Berge D, Nusse R, Spaargaren M and Pals ST: Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res. 68:6969–6977. 2008. View Article : Google Scholar : PubMed/NCBI
14	Huang Z, Fang Z, Zhen H, Zhou L, Amin HM and Shi P: Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 55:1876–1883. 2014. View Article : Google Scholar : PubMed/NCBI
15	Jaffe ES: The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology (Am Soc Hematol Educ Program). 2009:523–531. 2009.
16	Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B and Wolf I: KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res. 17:4254–4266. 2011. View Article : Google Scholar : PubMed/NCBI
17	Chen B, Ma X, Liu S, Zhao W and Wu J: Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist, in a dose-dependent manner. Cancer Biol Ther. 13:1221–1228. 2012. View Article : Google Scholar : PubMed/NCBI
18	Li XX, Huang LY, Peng JJ, Liang L, Shi DB, Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway. Int J Oncol. 45:611–618. 2014.PubMed/NCBI
19	Aviel-Ronen S, Rubinek T, Zadok O, Vituri A, Avivi C, Wolf I and Barshack I: Klotho expression in cervical cancer: Differential expression in adenocarcinoma and squamous cell carcinoma. J Clin Pathol. 69:53–57. 2016. View Article : Google Scholar : PubMed/NCBI
20	Lee J, Jeong DJ, Kim J, Lee S, Park JH, Chang B, Jung SI, Yi L, Han Y, Yang Y, et al: The anti-aging gene Klotho is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer. 9:1092010. View Article : Google Scholar : PubMed/NCBI
21	Chen T, Ren H, Thakur A, Yang T, Li Y, Zhang S, Wang T and Chen M: Decreased level of klotho contributes to drug resistance in lung cancer cells: Involving in klotho-mediated cell autophagy. DNA Cell Biol. 35:751–757. 2016. View Article : Google Scholar : PubMed/NCBI
22	Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al: Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer. 72:355–359. 2011. View Article : Google Scholar : PubMed/NCBI
23	Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q and Shu G: Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 44:795–801. 2013. View Article : Google Scholar : PubMed/NCBI
24	Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al: Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery. Lung Cancer. 74:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
25	Tilly H, da Gomes Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, et al: ESMO Guidelines Committee: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26:(Suppl 5). v116–v125. 2015. View Article : Google Scholar : PubMed/NCBI
26	Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, et al: Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008. View Article : Google Scholar : PubMed/NCBI
27	Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P and Amin HM: The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer. 14:532015. View Article : Google Scholar : PubMed/NCBI
28	Ligumsky H, Rubinek T, Merenbakh-Lamin K, Yeheskel A, Sertchook R, Shahmoon S, Aviel-Ronen S and Wolf I: Tumor suppressor activity of klotho in breast cancer is revealed by structure-function analysis. Mol Cancer Res. 13:1398–1407. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sun H, Gao Y, Lu K, Zhao G, Li X, Li Z and Chang H: Overexpression of Klotho suppresses liver cancer progression and induces cell apoptosis by negatively regulating wnt/β-catenin signaling pathway. World J Surg Oncol. 13:3072015. View Article : Google Scholar : PubMed/NCBI
30	Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H, Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI